Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Chosa Oncology

0.54 SEK-5.24 %19/11 15:36
Less than 1K followers

CHOSA

Spotlight Stock Market

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Short Selling
Investor views
Compare
-5.24 %
+6.69 %
-26.56 %
-31.74 %
-42.95 %
-48.38 %
-27.45 %
-97.72 %
-95.70 %

Chosa Oncology is a Swedish-Danish biotechnology company that develops solutions for personalized cancer treatment with a focus on diagnostics and drug formulation. The company targets healthcare providers and research actors and works internationally with partners and clinical projects. Chosa Oncology was founded in 2022 and is headquartered in Lund, Sweden.

Read more
Market cap
49.56M SEK
Turnover
542 SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Press releases
3rd party
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
19/11
2026

Interim report Q3'26

25/2
2027

Annual report '26

27/5
2027

General meeting '27

Regulatory press release2026-11-19 08:30

CHOSA Oncology AB - publicerar delårsrapport för tredje kvartalet 2026.

Chosa Oncology
Regulatory press release2026-11-16 19:55

The Board of Directors of Chosa Oncology AB resolves on a rights issue of units of approximately SEK 2.5 million fully covered by pre-subscription commitments

Chosa Oncology
Regulatory press release2026-11-16 19:55

Styrelsen i Chosa Oncology AB beslutar om företrädesemission av units om cirka 2,5 MSEK, fullt säkerställd genom teckningsåtaganden

Chosa Oncology

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
Followings and notifications on followed companies
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Press release2026-11-09 13:00

Chosa Oncology AB: CHOSA's ESMO 2026 Expert Meeting Highlights the Unmet Need for Personalized Platinum Therapy in Lung Cancer

Chosa Oncology
Press release2026-11-09 13:00

Chosa Oncology AB: CHOSAs expertmöte vid ESMO 2026 belyser behovet av individanpassad platinabehandling vid lungcancer

Chosa Oncology
Regulatory press release2026-11-04 10:35

CHOSA sluter avtal med CLIA som CHOSAs certifierade laboratoriepartner för Platin-DRP® i USA - de första intäkterna förväntas sommaren 2027

Chosa Oncology
Regulatory press release2026-11-04 10:35

CHOSA enters into an agreement with a CLIA-certified laboratory partner for Platin-DRP® in the USA - first revenue expected summer 2027

Chosa Oncology
Press release2026-10-08 10:33

Chosa Oncology AB: CHOSA receives 94 tumour samples from US patients to validate Platin-DRP® in lung cancer chemo-immunotherapy

Chosa Oncology
Press release2026-10-08 10:33

Chosa Oncology AB: CHOSA har tagit emot 94 tumörprover från amerikanska patienter för att validera Platin-DRP® vid lungcancer som behandlas med cellgifter och immunterapi

Chosa Oncology
Regulatory press release2026-08-27 14:40

Chosa Oncology AB: CHOSA Oncology accelerates value creation by entering into a commercially driven licensing agreement with Aida Oncology

Chosa Oncology
Regulatory press release2026-08-27 14:40

Chosa Oncology AB: CHOSA Oncology accelererar värdeskapandet genom ett kommersiellt drivet licensavtal med AIDA Oncology

Chosa Oncology
Regulatory press release2026-08-27 08:30

CHOSA Oncology AB - publicerar delårsrapport för andra kvartalet 2026.

Chosa Oncology
Regulatory press release2026-07-15 14:54

Chosa Oncology AB: CHOSA Oncology meddelar utfallet av utnyttjandet av teckningsoptioner av serie TO2

Chosa Oncology
Regulatory press release2026-07-15 14:54

Chosa Oncology AB: Chosa Oncology announces the result of exercise of warrants TO2

Chosa Oncology
Regulatory press release2026-07-13 17:17

Members of executive management participate in the ongoing warrant - exercise ending tomorrow

Chosa Oncology
Regulatory press release2026-07-10 08:30

Chosa Oncology AB: CHOSA Oncology appoints US commercialization Bill Cronin with a broad network in the oncology market, to accelerate launch of Platin-DRP

Chosa Oncology
Regulatory press release2026-07-10 08:30

Chosa Oncology AB: CHOSA utser Bill Cronin, med ett bred erfarenhet av onkologimarknaden, att leda den amerikanska kommersialiseringen för att accelerera lanseringen av Platin-DRP

Chosa Oncology
Third party research2026-07-01 10:18

CHOSA Oncology in connection with the TO2 warrant exercise - VH Corp

CHOSA Oncology’s CCO and board member Claus Frisenberg Pedersen visits Västra Hamnen and discusses the latest developments, what benefit CHOSA brings to cancer patients and how the company creates shareholder value. CHOSA is exercising its TO2 warrants...

Chosa Oncology
Press release2026-07-01 10:09

Västra Hamnen Market Focus: CHOSA Oncology in connection with the TO2 warrant exercise

Chosa Oncology
Regulatory press release2026-07-01 08:30

Chosa Oncology AB: CHOSA Oncology announces commencement of exercise period for TO2 warrants at the fixed price of SEK 0.78

Chosa Oncology